… explained that previous generalized treatment algorithms have become less … with obinutuzumab and rituximab (Rituxan; Genentech and Biogen), though … data from the CLL14 trial found that only 3 … regimens in contemporary CLL treatment, though they said some …

… of lenalidomide (Revlimid) and rituximab (Rituxan) yields a statistically significant and … study, concluded that the inMIND trial results are both statistically significant … 3-drug regimen "represents a potential new standard-of-care treatment …

… from new technology to treatment advances to important regulatory … Falchi, MD, a medical oncologist/hematologist and … FDA approval of epcoritamab-bysp (Epkinly) in combination with rituximab (Rituxan … treatment paradigm through the phase 3 EPCORE FL-2 trial …

… Lorenzo Falchi, MD, a medical oncologist /hematologist and … rituximab (Rituxan) and lenalidomide (Revlimid; R2) for the treatment of patients … phase 3 EPCORE FL-1 trial (NCT05409066), which met … lymphoma. Most notably, the FDA approval brings a highly …

… seeking accelerated approval for treatment of adult and pediatric … Course Having earned FDA orphan drug and breakthrough therapy … to partner Pierre Fabre Pharmaceuticals to assume global … are refractory to rituximab (Rituxan) after allogeneic hematopoietic …

… ).1 Chemoimmunotherapy (bendamustine plus rituximab [Rituxan]) was the most common in … from phase 1 Window-3 trial (NCT05495464), which evaluated acalabrutinib ( … patients]. [We sought to evaluate treatment patterns like] whether chemoimmunotherapy or …

… of the older antibody drug Rituxan. But the clearance of … Massachusetts-based biotech enrolled 194 people in the trial, randomizing half … addition to standard steroid treatments. Obexelimab’s main objective … in the Phase 3 trial and obexelimab’s FDA approval.

… trials (NCT02940262 and NCT02918357) supported the approval.13 Each trial … rituximab (Rituxan) received FDA approval as a treatment for … reduction in antihypertensive medications by at … Pharmaceuticals announces FDA approval of CAMCEVI ETM for the treatment …

… FDA-approved treatment, a therapy developed by biotechnology … medications. Rare Disease Approvals —Agios’s twice-daily pill … FDA approval. —The FDA approved an oral pellet formulation of the BioCryst Pharmaceuticals drug … the cancer drugs Rituxan and Revlimid. …

… Medical College of Wisconsin in Milwaukee. LOTIS-7 Trial Design Emerging trials … by the FDA and European Medicines Agency for … trial (NCT03274492) evaluated a modified regimen of rituximab (Rituxan … -drug conjugate loncastuximab tesirine for the treatment of …